Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP, At ATS 2026 International Conference

Benzinga Newsdesk www.benzinga.com Neutral 70.4%

Neg 0% Neu 70.4% Pos 0%

Comments

No comments yet. Be the first!